Exhibit 99.1 Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights ● The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee ...

Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – Genmab A/S (NASDAQ:GMAB) and Pfizer Inc. (NYSE:PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the tr ...

ProfoundBio, a Seattle-based biotech firm developing drugs to treat ovarian and endometrial cancers, will be acquired by publicly traded Danish drugmaker Genmab in a $1.8 billion all-cash deal expected to close in the first half of this year, the companies announced Wednesday. ProfoundBio, which is headquartered in Seattle and has a R&D center in China, specializes in antibody-drug conjugates (ADCs), agents that recognize a molecular target via an antibody and deliver a toxin or other compound to cells. It ...

KEY TAKEAWAYSDanish drugmaker Genmab said Wednesday that it is buying privately held U.S. biotech firm ProfoundBio for $1.8 billion in cash as it expands its pipeline of cancer treatments.The takeover will give Genmab access to a portfolio of next-generation antibody-drug conjugates, or ADCs, including one to treat ovarian cancer.Genmab's planned purchase comes as a spate of drug giants expand their focus on boosting their portfolios of drugs to treat cancer. Danish drugmaker Genmab A/S (GMAB) said Wednesda ...

James Gordon - JPMorgan Chase & Co Kaveri Pohlman - BTIG Peter Verdult - Citigroup Inc Sachin Jain - BofA Securities Jonathan Chang - Leerink Paul Jeng - Guggenheim Securities Peter Welford - Jefferies Genmab A/S (GMAB) Q4 2023 Results Conference Call February 14, 2024 12:00 PM ET Company Participants Jan van de Winkel - Co-Founder, President and Chief Executive Officer Anthony Mancini - Executive Vice President & COO Anthony Pagano - Executive Vice President & CFO Tahi Ahmadi Genmab - Executive VP, Chief M ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 1 ...

Exhibit 99.1 GENMAB 2023 ANNUAL REPORT Table of Contents | MANAGEMENT'S REVIEW | | | --- | --- | | Our 2030 Vision | 2 | | Chair's Statement | 2 | | Letter from the CEO | 3 | | 2023 at a Glance | 5 | | Consolidated Key Figures | 6 | | 2024 Outlook | 9 | | Our Strategy | 11 | | Who We Are | 13 | | Business Model | 15 | | Research and Development Capabilities | 15 | | Bringing Our Own Innovative Medicines to Patients | 16 | | Antibody Discovery and Development | 18 | | Products and Technologies | 18 | | Corpo ...

Genmab A/S (GMAB) Q3 2023 Earnings Conference Call November 7, 2023 12:00 PM ET Jan van de Winkel - Co-Founder, President & Chief Executive Officer Anthony Pagano - Executive Vice President & Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Tahi Ahmadi - Chief Medical Officer Company Participants Conference Call Participants Thanks Judith. Vikram, as you can hear, we are literally steaming about all these three programs. So we're very excited and ...

Quarter End Results Forward-looking This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our ...

Exhibit 99.1 Genmab Announces Financial Results for the First Nine Months of 2023 November 7, 2023 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2023 Highlights "With regulatory approvals in Japan and Europe, EPKINLY/TEPKINLY is the first Genmab- owned medicine to become available to patients outside of the United States. In addition to being an important milestone for Genmab, these approvals mark an important milestone for patients in these territories who are in need of ...